Membranous Nephropathy
Conditions
Interventions
Intervention group:Maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD
Control group:Maximum tolerable dose of ACEI/ARB
Sponsors
General Hospital of Ningxia Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Older than 18 years of age; 2. Diagnosed with membranous nephropathy, with eGFR > 60 mL/min/1.73 m2, and UACR 30-5000mg/g; 3. Receiving a stable maximum tolerated dose of ACEi or ARB for at least 4 weeks.
Exclusion criteria
Exclusion criteria: 1. Diagnosed with type 1 or type 2 diabetes; 2. Any other primary or secondary kidney disease, receiving hormone, immunosuppressant treatment within 3 months prior to screening, or biological agents within 6 months; 3. Severe liver damage and heart failure; active malignancy, pregnancy, history of organ transplantation, etc. 4. Unable to discontinue the use of eplerenone, spironolactone, esaxerenone, or potassium-sparing diuretics within 4 weeks prior to enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine Albumin-to-Creatinine Ratio, UACR; | — |
Secondary
| Measure | Time frame |
|---|---|
| 24-hour urine protein;Estimated Glomerular Filtration Rate; | — |
Countries
China
Contacts
Public ContactXiaoling Zhou
General Hospital of Ningxia Medical University
Outcome results
None listed